

NEWS RELEASE

Successful FDA Inspection with No 483 Issued to Powder Pharmaceuticals

[14 March 2016, Hong Kong] Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950) an integrated research-driven and market-oriented pharmaceutical group in China is pleased to announce that Powder Pharmaceuticals, Incorporated ("PPI"), an associated company of the Group, has successfully completed an U.S. Food and Drug Administration (FDA) inspection to its manufacturing facility in Hong Kong resulting with NO 483 observation issued.

The inspection covered all relevant areas of the Good Manufacturing Practice (GMP) quality system required by the regulatory agency. The audit carried out by the FDA Investigator lasted four days, instead of the seven days which was initially planned. Throughout the inspection, the inspector spoke positively of many of our initiatives and actions as well as a couple constructive recommendations for future improvement. An FDA inspection without observation confirms the company compliance with the world-class GMP standard. It also reflects the years of hard work that the PPI team of manufacturing and quality professionals has dedicated towards the goal to continuously improve and develop quality pharmaceutical product.

About Zingo®

Zingo® (lidocaine hydrochloride monohydrate) is an amide local anesthetic indicated for use on intact skin to provide local analgesia prior to venipuncture or peripheral intravenous cannulation in children 3–18 years of age and to provide topical local analgesia prior to venipuncture in adults. The rapid onset of analgesia in 1-3 minutes provides care givers and patients the opportunity for a pain-free and needle-free access procedure. Clinical trials have shown a statistical difference in pain scores during needle access procedures when using Zingo® versus a placebo system. Zingo® is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. It is not to be used around the eyes or on body orifices, mucous membranes, or on areas with a compromised skin barrier.

Zingo® should only be used on skin locations where an adequate seal can be maintained. Adverse reactions in clinical studies of Zingo® primarily included application-site reactions (i.e., hypoaesthesia, burning, and venipuncture site hemorrhage) and dizziness (which occurred in 0.9% of active treated subjects vs. 0.7% of those administered placebo).

About Powder Pharmaceuticals, Incorporated ("Powder")

Powder is an associated company of Lee's Pharmaceutical Holdings Limited based in Hong Kong and is developing products that utilize a proprietary needleless, painless, powder delivery technology. Powder intends to supply Zingo® globally through international business partners. Powder has successfully obtained approval from U.S. FDA in July 2013 for the manufacturing facilities in Hong Kong to produce Zingo® and market the product to U.S.

About Lee's Pharmaceutical Holdings Limited ("Lee's Pharm")

Lee's Pharm is a research-based Hong Kong biopharmaceutical company listed in Hong Kong with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's Pharm development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharm is available at www.leespharm.com.

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For Contact:

Vivian Fung
Licensing and Regulatory Manager
+852-2314-6500
info@leespharm.com